Cell therapy company Immusoft Corporation announced on Wednesday the election of Robert Hayes, PhD as its chief scientific officer.

Dr Hayes will lead the company's preclinical research and spearhead the near-term advancement of ISP-001 for the treatment of Mucopolysaccharidosis type I (MPS I) and additional Immune System Programming (ISP) candidates into clinical development.

Most recently, Dr Hayes was the head of Biologics at Amgen Inc (NASDAQ: MGN), a multinational biopharmaceutical company.

Previously, Dr Hayes has worked as vice president & venture leader of Centyrex, a biotech Venture within Janssen R&D, as well as senior director of Protein Engineering at Johnson & Johnson and Director of Antibody Engineering at Xencor.